Neglected Tropical Disease News and Research

RSS

Baxter International acquires drug candidate developed to treat sickle cell disease

A drug candidate developed by researchers at the NIH's National Center for Advancing Translational Sciences and its collaborators to treat sickle cell disease has been acquired by Baxter International's BioScience business.

11 Jul 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

A-PARADDISE consortium obtains funds to develop innovative therapies for neglected parasitic diseases

The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinated by Inserm, has just obtained funds of €6 million from the European Commission to conduct large-scale testing of innovative therapies against four neglected parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.

4 Mar 2014

Selcia, University of Edinburgh collaborate to develop novel treatments for sleeping sickness

An initiative is under way to develop new drugs for a devastating tropical disease that threatens almost 70 million people in Africa.

4 Feb 2014

New drug helps children and young adults who have severe pain from sickle cell disease

Saint Louis University researchers are studying whether ReoPro® (abciximab), a drug currently given to heart patients undergoing angioplasties to open blocked arteries, also could help children and young adults who have severe pain from sickle cell disease.

23 Jan 2014

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Nearly 3.3 billion people, a little less than half of our world’s population, are at risk of malaria, TB and what we call “neglected tropical diseases”—diseases caused by worms, parasites, viruses and bacteria like Chagas disease, river blindness, elephantiasis, sleeping sickness, etc.

24 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

PLOS and DNDi to launch collection of neglected tropical diseases at 10-year anniversary of DNDi

As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to be launching a special Collection-PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development)-to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10-year anniversary of DNDi.

28 Nov 2013

GHIT Fund grants US$5.7 million to six global partnerships working on vaccines against malaria

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, announced today grants of US$5.7 million to six global partnerships working on innovative drugs and vaccines against malaria, tuberculosis and Chagas disease.

8 Nov 2013

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

In an effort to develop and deliver treatments for children with tuberculosis—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments.

30 Oct 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

Four new pre-clinical drug development projects at NIH develop treatment for rare disease

Four new pre-clinical drug development projects at the National Institutes of Health will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

13 Sep 2013

DFID awards 5-year grant to DNDi to advance research and development for neglected diseases

The UK Department for International Development (DFID) has announced its renewed support to the Drugs for Neglected Diseases initiative (DNDi), allocating a total of - 30 million (- 35 million) over the coming five years (2013-2018) to DNDi's Research & Development (R&D) portfolio to fight neglected diseases.

22 Aug 2013

DNDi and Institut Pasteur Korea collaborates to spur fight against neglected diseases

A collaboration between the Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) to spur the fight against neglected diseases has been established.

14 Aug 2013

Scientists to explore student-driven research model for Distributed Drug Discovery

Purdue University Indianapolis (IUPUI) will host scientists from around the world next week for the first-ever workshop devoted to Distributed Drug Discovery, an innovative, student-driven research program quickly becoming a high-impact, low-cost teaching model.

20 Jul 2013

WHO includes new paediatric therapeutic options to EMLc

This week the World Health Organization released its newly updated 4th WHO Model List of Essential Medicines for Children, in which three treatments developed by the Drugs for Neglected Diseases initiative and its partners have now been included.

12 Jul 2013

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society Conference, include new antiretroviral therapy recommendations for HIV-infected children, and will mean that more children will be on better treatments.

1 Jul 2013

Sustained engagement, partnership needed to implement new treatments for neglected diseases

Days after two landmark resolutions were adopted at the World Health Assembly - on neglected tropical diseases and on research and development, financing and coordination for the health needs of developing countries - over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade.

6 Jun 2013

Leptospirosis: The newest public health threat in Africa

The newest public health threat in Africa, scientists have found, is coming from a previously unknown source: the banded mongoose.

15 May 2013